embolization and invasive surgical procedures (myomectomy & hysterectomy). The U.S.
Uterine Fibroids market is expected to reach USD 39,993.2 million in 2022.
Key Finding
The U.S. Uterine Fibroid Market and is expected to reach USD 39,993.2 million by
2022.
By Type, Intramural Fibroids holds the largest market share of U.S. Uterine
Fibroid Market and is expected to reach USD 14,972.5 million by 2022.
By Treatment, hysterectomy holds the largest market share of U.S. Uterine
Fibroid Market and is expected to reach USD 8,042.3 million by 2022.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2394 .
Key Players:
AstraZeneca (England), Cook Medical Inc. (US), Boston Scientific Corporation (US), GE
Healthcare (U.K.), AbbVie Inc. (U.S.), Hologic (U.S.) and others.
U.S. Uterine Fibroid Market:
In the coming years, it is expected that the U.S. Uterine fibroid Market will advance with
higher growth rate as compared to previous years. The large number of women affected
by the problem and the large number of hysterectomy procedure are done to treat the
symptoms are the major factors driving the market for uterine fibroid market.
Segmentation:
U.S. Uterine Fibroid Market has been segmented on the basis of type which comprises of
Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others. On the basis
of diagnosis the market is segmented into Medical Resonance Imaging (MRI) scanners,
Computed tomography (CT), Ultrasounds and others. On the basis of treatment the
market is segmented into Uterine Fibroid Embolization, Magnetic Resonance Guided
Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy.
Regional Analysis:
The U.S. market for uterine fibroids is growing steadily. The market for uterine fibroids is
growing with the CAGR of 3.24% during the forecast period from 2016-2022. Treatment
with both drug and surgery accounted for the largest market share by treatment while
treatment with only surgery is the second largest market for uterine fibroid, by
treatment. Treatment with only pharmacotherapy is the fastest growing market, which is
expected to grow at a CAGR of 18.96% during the forecast period of 2016-2022. The
reason for this high growth is the positive clinical trial results of some drugs which will
shoot the uterine fibroid market for pharmacotherapy.
Brief TOC:
Topic 1 Introduction
1.1.1 Prevalence of the Uterine Fibroids in U.S. 8
Topic 2 Scope of Study
2.1 Research Objective 10
2.2 Assumptions & Limitations 10
2.2.1 Assumptions 10
2.2.2 Limitations 10
2.3 Market Structure 11